Back to News
Market Impact: 0.2
Tempest Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform
Source: GlobeNewswire
Healthcare & BiotechTechnology & Innovation
Tempest said the transaction complements its CD7-targeted lipid nanoparticle in vivo CAR-T delivery platform. The company plans to bring the platform into clinical testing later this year, representing a modest positive development for its cell-therapy pipeline.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
TPST0.35
More News
- Tempest Therapeutics stock surges on Senlang CAR-T deal
- Tempest Therapeutics enters option deal for CAR-T platform
- Two camps have emerged in the debate over AI safety and regulation
- AWS says it can't restore service to Bahrain, UAE facilities 6 months after Iran strikes
- Push for AI regulation mounts as talk of AI’s ‘existential’ risks go mainstream. But Trump resists calls for a slowdown
- Wells Fargo sees improvement in a key metric — plus, Lilly gets praise beyond GLP-1s
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Run Cost-Controlled Financial Research in AllMind Agent Studio
- State of Public Markets, June 2026: Higher for Longer Meets the AI Supercycle